Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072096 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
A Phase 4 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 4
- Development phase
- 192
- Enrollment target
NCT02072096 is a Phase 4 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 192 participants.
The verdict
NCT02072096, a Phase 4 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 192 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.
Interventions
- DRUG Metformin
- DRUG Pioglitazone
- DRUG Linagliptin
- DRUG Glimepiride
- DRUG Acarbose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072096
The ClinicalTrials.gov registry entry for NCT02072096 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT02072096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02072096 about?
NCT02072096 is a clinical study titled "A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)". The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it i...
What is the current status of trial NCT02072096?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 192 participants. The study started on 2014-02. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02072096?
The interventions under investigation include: Metformin (DRUG), Pioglitazone (DRUG), Linagliptin (DRUG), Glimepiride (DRUG), Acarbose (DRUG).
Who is sponsoring clinical trial NCT02072096?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.